AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2018 • Savara Inc • Pharmaceutical preparations • Texas
This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of August 3, 2018, by and among Savara Inc., successor-in-interest to Aravas Inc. (the “Company”) and Taneli Jouhikainen (the “Executive”).
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2018 • Savara Inc • Pharmaceutical preparations • Texas
This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of August 3, 2018, by and among Savara Inc., successor-in-interest to Aravas Inc. (the “Company”), and David Lowrance (the “Executive”).
Amendment No. 1 To the RESEARCH COLLABORATION AND LICENSE AGREEMENT Between SAVARA INC. and PARI Pharma GmbHLicense Agreement • August 9th, 2018 • Savara Inc • Pharmaceutical preparations
This first amendment (“Amendment No. 1”) to the Research Collaboration and License Agreement, effective as of 7th day of November 2014, between PARI Pharma GmbH, Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Serendex Pharmaceuticals A/S, Slotsmarken 17, 2.tv., DK-2970 Hørsholm, Denmark (“Serendex”) (the “Agreement”), is made effective as of May 23rd, 2018 (“Amendment No. 1 Effective Date”) by and between PARI and Savara Inc. with a principal place of business at 6836 Bee Cave Road, Building 3, Suite 200, Austin, TX, 78746, United States of America (“Savara”). PARI and Savara shall be referred to each as a “Party” and collectively as the “Parties”.
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2018 • Savara Inc • Pharmaceutical preparations • Texas
This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of August 3, 2018, by and among Savara Inc., successor-in-interest to Aravas Inc. (the “Company”), and Robert Neville (the “Executive”).
